loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations

Ind-Swift Laboratories Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Ind-Swift Laboratories Ltd. 05 Feb 2026 12:28 PM

Q3FY26 Quarterly Result Announced for Ind-Swift Laboratories Ltd.

Pharmaceuticals company Ind-Swift Laboratories announced Q3FY26 results

  • Total Revenue: Rs 177.06 crore against Rs 168.3 crore during Q2FY26, change 5%.
  • EBITDA: Rs 9.11 crore against Rs 8.55 crore during Q2FY26, change 7%.
  • EBITDA Margin: 5.95% for Q3FY26.
  • PBT: Rs 17.61 crore against Rs 11.06 crore during Q2FY26, change 59%.
  • PAT: Rs 10.74 crore against Rs 8.76 crore during Q2FY26, change 23%.
  • PAT Margin: 6.07% for Q3FY26.

N.R. Munjal Chairman & Whole Time Director, said: “Revenue remained stable for Q3FY26, while a reduction in raw material and employee benefit expenses drove a 6.60% increase in Operating EBITDA and an Operating EBITDA margin expansion of approximately 48 BPS. This improvement in operational efficiency, translated to a 22.60% rise in Net Profit (PAT) QoQ.

Ind-Swift Laboratories Ltd has successfully completed a historic strategic reset through the Rs 1,650 crore divestment of its API & CRAMS business. This decisive action, combined with the merger of Ind-Swift Limited into ISLL, has transformed the company into a Net Debt Free entity with a unified operational structure. Currently, we operate as a Pure-Play Formulations Platform with a solid Revenue base of Rs 550 crore, driven primarily by high-quality exports. The restructuring has consolidated our capabilities across manufacturing, R&D and distribution, positioning the entire organization for scalable, capitalefficient growth.

Further we are accelerating execution across high-growth engines by strengthening CDMO visibility through the FY27 accretive Viatris partnership and expanding our Own-Brand footprint in UAE and Central Asia with 400 registered products. Supported by high-margin segments like Ethical (76% GM), Own-Brand (51% GM) and CMO (42% GM) we are targeting sustained expansion to Double Revenue by FY29 while delivering consistent profitability.”

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app